标题
New advances in targeted gastric cancer treatment
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 30, Pages 6776
出版商
Baishideng Publishing Group Inc.
发表日期
2016-08-08
DOI
10.3748/wjg.v22.i30.6776
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- LBA15A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER
- (2017) K. Muro et al. ANNALS OF ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular targeted therapy for the treatment of gastric cancer
- (2016) Wenting Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application
- (2016) Kaichun Li et al. Gastroenterology Research and Practice
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
- (2015) Hung Huynh et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer
- (2015) Feng Du et al. MEDICINE
- Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
- (2015) Christopher D. Hart et al. Nature Reviews Clinical Oncology
- Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond
- (2015) Audrey H Choi WORLD JOURNAL OF GASTROENTEROLOGY
- Second-line treatment of metastatic gastric cancer: Current options and future directions
- (2015) Dheepak Kanagavel WORLD JOURNAL OF GASTROENTEROLOGY
- Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
- (2015) Rodrigo Dienstmann et al. CANCER RESEARCH
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype
- (2014) Ana Ferro et al. EUROPEAN JOURNAL OF CANCER
- Apatinib for the treatment of gastric cancer
- (2014) Ruixuan Geng et al. EXPERT OPINION ON PHARMACOTHERAPY
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
- (2014) Taroh Satoh et al. Gastric Cancer
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
- (2014) Allyson J. Ocean et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines
- (2014) Sung Bae et al. ONCOLOGY REPORTS
- Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial
- (2014) Shingo Takano et al. OncoTargets and Therapy
- Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer?
- (2013) Lorenzo Fuccio et al. ANNALS OF INTERNAL MEDICINE
- P-0111 * PERTUZUMAB, TRASTUZUMAB AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER: AN INTERNATIONAL PHASE III STUDY (JACOB)
- (2013) P. Hoff et al. ANNALS OF ONCOLOGY
- Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy
- (2013) Minhao Fan et al. BREAST CANCER RESEARCH AND TREATMENT
- Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
- (2013) N C Tebbutt et al. BRITISH JOURNAL OF CANCER
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
- (2013) B. Holkova et al. CLINICAL CANCER RESEARCH
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Matrix Metalloproteinase-14 Is a Negative Prognostic Marker for Patients with Gastric Cancer
- (2013) Liang He et al. DIGESTIVE DISEASES AND SCIENCES
- Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
- (2013) K.-W. Lee et al. INVESTIGATIONAL NEW DRUGS
- Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers
- (2013) ClaraL Sampieri et al. Journal of Cancer Research and Therapeutics
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- New agents in renal cell carcinoma
- (2013) Raetasha Dabney et al. Targeted Oncology
- Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer
- (2013) Jiang Liu et al. OncoTargets and Therapy
- Current questions for the treatment of advanced gastric cancer
- (2012) A. Cervantes et al. CANCER TREATMENT REVIEWS
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- The benefit of mass eradication ofHelicobacter pyloriinfection: a community-based study of gastric cancer prevention
- (2012) Yi-Chia Lee et al. GUT
- A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
- (2012) C. Gómez-Martín et al. INVESTIGATIONAL NEW DRUGS
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: A Novel Treatment for Metastatic Melanoma
- (2011) Morgan E Culver et al. ANNALS OF PHARMACOTHERAPY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells
- (2011) Hong Qiu et al. CANCER LETTERS
- mTOR as a therapeutic target in patients with gastric cancer
- (2011) Salah-Eddin Al-Batran et al. INTERNATIONAL JOURNAL OF CANCER
- Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
- (2011) Yasushi Goto et al. INVESTIGATIONAL NEW DRUGS
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
- (2011) Heribert Juergens et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
- (2011) Mitsuru Sasako et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
- (2011) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts
- (2011) Yunpeng Liu Molecular Medicine Reports
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
- (2011) Yesid Alvarado et al. Targeted Oncology
- A review of PARP inhibitors: from bench to bedside
- (2010) C. Underhill et al. ANNALS OF ONCOLOGY
- 7th Edition of the AJCC Cancer Staging Manual: Stomach
- (2010) Kay Washington ANNALS OF SURGICAL ONCOLOGY
- H. pylori Infection Is a Key Risk Factor for Proximal Gastric Cancer
- (2010) Jan Bornschein et al. DIGESTIVE DISEASES AND SCIENCES
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Role ofHelicobacter pyloriinfection in gastric cancer pathogenesis: A chance for prevention
- (2010) Peter MALFERTHEINER et al. Journal of Digestive Diseases
- Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)
- (2010) Aminah Jatoi et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer
- (2009) S. Yang et al. MOLECULAR CANCER THERAPEUTICS
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of Insulin-Like Growth Factor Type 1 Receptor and Epidermal Growth Factor Receptor in Patients with Advanced Gastric Cancer
- (2008) Junichi Matsubara et al. ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search